Assessment of tumour-agnostic therapies in basket trials

There are notable differences between the two countries, for instance with regards to the French agency asking for prospectively planned real-world comparator data if randomised trials are not feasible, and the English HTA agency perhaps being more pragmatic for patient access to treatment and provi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The lancet oncology 2022-01, Vol.23 (1), p.e7-e7
Hauptverfasser:	Popat, Sanjay, Ramagopalan, Sreeram V, Ray, Joshua, Roze, Stéphane, Subbiah, Vivek
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer therapies Clinical trials Humans Molecular Targeted Therapy Mutation Neoplasms - drug therapy Oncology Patients Pharmaceuticals Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!